Perspectives & practice insights
Clinical commentary, education, and community stories from across the Alliance.
FDA Approves OTC Differin® Epiduo® for Acne Management
Galderma has announced that the U.S. Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% / Benzoyl Peroxide 2.5%) for over-the-counter (OTC) use in individuals aged 12 years and older. This Prescriptio
FDA Approves ZORYVE® (roflumilast) Cream 0.05% for Atopic Dermatitis in Young Children Ages 2-5
Arcutis Biotherapeutics, Inc. has announced the FDA approval of ZORYVE® (roflumilast) cream 0.05% for the treatment of mild to moderate atopic dermatitis in children aged 2 to 5 years. This approval is supported by findings from the INTEGUM
Oct 12, 2025Novartis Receives FDA Approval for Rhapsido® (Remibrutinib) as a Novel Treatment for Chronic Spontaneous Urticaria
On September 30, 2025, Novartis announced the FDA approval of Rhapsido® (remibrutinib), marking it as the first oral Bruton’s tyrosine kinase inhibitor (BTKi) approved for the treatment of chronic spontaneous urticaria (CSU) in adults who r
Oct 11, 2025FDA Approves TREMFYA® for Pediatric Psoriasis and Psoriatic Arthritis
In a significant advancement for pediatric care, the U.S. Food and Drug Administration (FDA) has approved TREMFYA (guselkumab) for the treatment of children aged 6 years and older with moderate to severe plaque psoriasis (PsO) or active pso
Oct 09, 2025Efficacy and Safety of Ruxolitinib Cream in Pediatric Atopic Dermatitis: TRuE-AD3 Study Findings
A phase 3 study (TRuE-AD3) evaluated the efficacy and safety of ruxolitinib cream in children aged 2-11 years with mild-to-moderate atopic dermatitis (AD). A total of 330 children were randomized to receive either vehicle, 0.75%, or 1.5% ru
Oct 03, 2025FDA Approves Otezla® for Pediatric Psoriatic Arthritis in Patients 6 Years and Older
The FDA has granted approval for Otezla® (apremilast) to treat active psoriatic arthritis in pediatric patients aged 6 years and older who weigh at least 20 kg. This landmark approval is backed by robust evidence from controlled clinical tr
Aug 15, 2025The efficacy of longer-term lebrikizumab treatment
This study evaluated the long-term efficacy of lebrikizumab in patients with moderate-to-severe atopic dermatitis who did not meet early treatment response criteria by week 16. Despite 38.1% of patients not reaching the defined response thr
Jun 17, 2025Rilzabrutinib Shows Promise for Treating Tough Cases of Chronic Spontaneous Urticaria
The phase 2 RILECSU clinical trial has brought encouraging news for patients suffering from chronic spontaneous urticaria (CSU) that doesn’t respond well to standard antihistamines. Rilzabrutinib, an investigational oral Bruton tyrosine kin
Jun 03, 2025Topical steroid withdrawal diagnostic criteria defined by NIH researcher
Researchers at the National Institutes of Health (NIH) have uncovered new insights into dermatitis caused by topical steroid withdrawal (TSW), revealing that it is distinct from eczema and linked to high levels of a key chemical compound ca
May 05, 2025Deucravacitinib in Moderate to Severe Plaque Psoriasis: 5-Year Long Term Safety and Efficacy Results From the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials Including Laboratory Parameters
Deucravacitinib demonstrated a consistent safety profile over 5 years with more than 5,000 patient years of exposure, showing no increase in adverse events, serious adverse events, or the emergence of new safety signals. Rates of serious in
Apr 28, 2025Lebrikizumab Improves Itch, Itch Interference on Sleep, and Skin Pain in Patients With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab
In the open-label ADapt trial, lebrikizumab demonstrated significant improvements in managing symptoms of AD like itch, sleep disruption due to itching, and skin pain in patients who had previously been treated with dupilumab. For those who
Apr 15, 2025